MAPT and Mental deterioration: Notably, in a 20-year longitudinal study involving a diverse cohort of older adults without dementia, APOE4 carrier status was shown to significantly accelerate cognitive decline in the presence of elevated blood-based biomarkers of neurodegeneration (total tau, NfL, GFAP) [182].